Date:10/1/2009

nses 553,640 583,024 2,450,010 2,758,737 Litigation expense 174,000 - 278,000 - ------- ------ ------- ------ Total operating expenses 5,124,628 5,546,509 18,501,628 20,591,971 --------- --------- ---------- ---------- Operating loss from continuing operations (971,954) (1,359,639) (2,497,674) (2,826,419) Total other income (loss) 235,510 (32,366) 1,816,618 105,584 ------- ------- --------- ------- Loss from continuing operations before minority interest and income taxes (736,444) (1,392,005) (681,056) (2,720,835) Minority interest in net income (loss) of consolidated subsidiaries 10,911 (1,404) 43,878 46,176 ------ ------ ------ ------ Loss from continuing operations before income taxes (747,355) (1,390,601) (724,934) (2,767,011) Income tax provision (benefit) 56,196 1,023,149 (178,483) 656,712 ------ --------- -------- ------- Net loss from continuing operations (803,551) (2,413,750) (546,451) (3,423,723) -------- ---------- -------- ---------- Income from discontinued operations, net of tax 298,986 63,421 670,858 535,912 Gain on sale of discontinued operations, inclusive of a tax benefit 2,681,760 0 2,681,760 0 --------- ------ --------- ------ Net income from discontinued operations, net of tax
'/>"/>

SOURCE Misonix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors